Oxytocin reverses ovariectomy-induced osteopenia and body fat gain.

Endocrinology (2014-02-11)
Guillaume E Beranger, Didier F Pisani, Julien Castel, Mansour Djedaini, Séverine Battaglia, Jérôme Amiaud, Florian Boukhechba, Gérard Ailhaud, Jean-François Michiels, Dominique Heymann, Serge Luquet, Ez-Zoubir Amri
ABSTRACT

Osteoporosis and overweight/obesity constitute major worldwide public health burdens that are associated with aging. A high proportion of women develop osteoporosis and increased intraabdominal adiposity after menopause. which leads to bone fractures and metabolic disorders. There is no efficient treatment without major side effects for these 2 diseases. We previously showed that the administration of oxytocin (OT) normalizes ovariectomy-induced osteopenia and bone marrow adiposity in mice. Ovariectomized mice, used as an animal model mimicking menopause, were treated with OT or vehicle. Trabecular bone parameters and fat mass were analyzed using micro-computed tomography. Herein, we show that this effect on trabecular bone parameters was mediated through the restoration of osteoblast/osteoclast cross talk via the receptor activator of nuclear factor-κB ligand /osteoprotegerin axis. Moreover, the daily administration of OT normalized body weight and intraabdominal fat depots in ovariectomized mice. Intraabdominal fat mass is more sensitive to OT that sc fat depots, and this inhibitory effect is mediated through inhibition of adipocyte precursor's differentiation with a tendency to lower adipocyte size. OT treatment did not affect food intake, locomotors activity, or energy expenditure, but it did promote a shift in fuel utilization favoring lipid oxidation. In addition, the decrease in fat mass resulted from the inhibition of the adipose precursor's differentiation. Thus, OT constitutes an effective strategy for targeting osteopenia, overweight, and fat mass redistribution without any detrimental effects in a mouse model mimicking the menopause.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N,N-Dimethylformamide, anhydrous, 99.8%
Sigma-Aldrich
N,N-Dimethylformamide, for molecular biology, ≥99%
Sigma-Aldrich
N,N-Dimethylformamide, suitable for HPLC, ≥99.9%
Sigma-Aldrich
N,N-Dimethylformamide, ACS reagent, ≥99.8%
Supelco
Hematoxylin
Supelco
Dimethylformamide, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
Sigma-Aldrich
N,N-Dimethylformamide, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
N,N-Dimethylformamide, ReagentPlus®, ≥99%
Sigma-Aldrich
Oxytocin
Sigma-Aldrich
N,N-Dimethylformamide, biotech. grade, ≥99.9%
Supelco
N,N-Dimethylformamide, analytical standard
Sigma-Aldrich
Oxytocin, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin)
Sigma-Aldrich
Oxytocin acetate salt hydrate, ≥97% (HPLC)
Oxytocin, European Pharmacopoeia (EP) Reference Standard
USP
Oxytocin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
N,N-Dimethylformamide, suitable for HPLC, ≥99.9%
Sigma-Aldrich
N,N-Dimethylformamide, ACS reagent, ≥99.8%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.